Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2006-04-24
2009-11-10
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S387100, C530S388100, C530S388800, C424S130100
Reexamination Certificate
active
07615372
ABSTRACT:
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.
REFERENCES:
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 6090930 (2000-07-01), Wallace et al.
patent: 6146894 (2000-11-01), Nicolaides et al.
patent: 2006/0121541 (2006-06-01), Grasso et al.
patent: 0 239 400 (1994-08-01), None
patent: 90/07861 (1990-07-01), None
patent: WO94/11023 (1994-05-01), None
patent: 95/24483 (1995-09-01), None
patent: 02/054856 (2002-07-01), None
patent: WO2004/078942 (2004-09-01), None
patent: WO2005/086713 (2005-09-01), None
patent: WO2006/017759 (2006-02-01), None
patent: WO2006/060719 (2006-06-01), None
patent: WO2006/116451 (2006-11-01), None
Sun et al, 2000, Cancer Immunol Immunother, 48: 595-602.
Banapour B et al, 1987 (J Immunol, 139 (12): 4027-4033).
ST Croix et al in MPSRCH search result, 2008, US-11.410.472.2.rag.RESULT 1, and US-11.410.472.1.rag.RESULT 2, pp. 1- 5.
Bagley, et al., “Human endothelial precursor cells express tumor endothelial marker 1/endothesialin/CD248”,Mol Cancer Ther2008; 7(8) 2536-2546.
Bagley, et al., “Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization”,Microvasc Res., 2008 1-9.
Brady, et al. “Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors”,JNL of Neuropatholgy and Experimental Neurology, 2004; 63(12) , 1274-1283.
Marty, et al., “Isolation and characterization of a scfv antibody specific for tumor endothelial marker 1 (tcm 1), a new reagent for targeted tumor thcrapy”,Cancer Letters, (2006), 235(2), 298-308.
Christian, et al. “Molecular cloning and characterization of endosialin, a c-type lectin-like cell surface receptor of tumor endothelium”,Jnl of Bio Chem., American Soc of Biolchem Biologists, (2001) 276 (10) 7408-7414.
Tomkowicz,et al., “Interaction of endosialin.tem1 with extracellular matrix proteins medicates cell adhesion and migration”,Proceedings of the Natl. Acad. of Sci, USA, (2007), 104(46), 17965-17970.
Boerner, P., et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J. of Immunol., 1997, 147, 86-95.
Brady et al., “Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors,” J Neuropathol. Exp. Neurol., 2004, 63, 1274-1283.
Cole, et al. in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, pp. 77-96.
Conejo-Garcia, J.R., et al., “Vascular leukocytes contribute to tumor vascularization,” Blood, 2005, 105(2), 679-681.
Das, A., et al., “Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition,” Prog. Retin. Eye Res., 2003, 22(6), 721-748.
Dhanabal, “Anti-angiogenic therapy as a cancer treatment paradigm,” Curr. Med. Chem. Anti-Canc. Agents, 2005, 5, 115-130.
Garmestani, K. et al., “Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides,” Nucl. Med. Biol., 2001, 28, 409-418.
Hanahan, D., et al., “The hallmarks of cancer,” Cell, 2000, 100(1), 57-70.
Huang, C., et al., “Construction of representative immunoglobulin variable region cDNA libraries from human peripheral blood lymphocytes without in vitro stimulation,” J. of Immunol. Methods, 1991, 141, 227-236.
Jones, P.T., et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 1986, 321, 522-525.
Khazaeli, M.B., et al., “Human immune response to monoclonal antibodies,” J. of Immunother., 1994, 15, 42-52.
Kikuchi, Y. et al., “Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma,” Leuk. Res., 2005, 29, 445-450.
Köhler, G., et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 1975, 256, 495-497.
Kozbor, D., et al., “The production of monoclonal antibodies from human lymphocytes,” Immunol. Today, 1983, 4(3), 72-79.
Kreitman, R. J., et al., “Immunotoxins for targeted cancer therapy,” Adv. Drug Del. Rev., 1998, 31, 53-88.
Kusano, A. et al., “Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies,” Anticancer Res., 1993, 13(6A), 2207-2212.
Marks, J. D. et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,” J. Mol. Biol., 1991, 222, 581-597.
Morrison, S. L., et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,” Proc. Natl. Acad. Sci. USA, 1984, 81, 6851-6855.
Niwa, R. et al., “Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma,” Cancer Res., 2004, 64, 2127-2133.
Orlandi, R., et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Natl. Acad. Sci. USA, 1989, 86, 3833-3837.
Paleolog, E.M., et al., “Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target,” Angiogenesis, 1998/1999, 2, 295-307.
Persson, M. A. A., et al., “Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning,” Proc. Nat. Acad. Sci. USA, 1991, 88, 2432-2436.
Peters et al., “Contribution of bone marrow-derived endothelial cells to human tumor vasculature,” Nat. Med., 2005, 11, 261-262.
Presta, L. G., “Antibody engineering,” Curr. Op. Struct. Biol., 1992, 2, 593-596.
Queen, C., et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc. Nat. Acad. Sci. USA, 1989, 86, 10029-10033.
Reichmann, L., et al., “Reshaping human antibodies for therapy,” Nature, 1988, 332, 323-327.
Rettig, W. J. et al., “Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer,” Proc Natl. Acad Sci USA, 1992, 89(22), 10832-10836.
Scott, A. M. et al., “Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma,” Cancer Immun., 2005, 22, 5(3), 1-12.
St. Croix, B., et al., “Genes expressed in human tumor endothelium,” Science, 2000, 289(5482), 1197-1202.
Tempest, P.R., et al., “Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo,” Biotechnology, 1991, 9, 266-271.
Verhoeyen, M., et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science, 1988, 239, 1534-1536.
Wilkinson-Berka, J.L., “Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide,” Curr. Pharm. Des., 2004, 10(27), 3331-3348.
Wolff, E. A. et al., “Monoclonal antibody homodimers: enhanced antitumor activity in nude mice,” Cancer Res., 1993, 53, 2560-2565.
Yancopoulos, G.D., e
Grasso Luigi
Nicolaides Nicholas C.
Sass Philip M.
Davis Minh-Tam
Helms Larry R.
Morphotek Inc.
Woodcock & Washburn LLP
LandOfFree
Antibodies with immune effector activity and that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies with immune effector activity and that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies with immune effector activity and that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096974